Topical Treatment of Scalp Psoriasis With the Fixed Combination of Calcipotriol and Betamethason (Xamiol® Gel)
1 other identifier
observational
724
1 country
1
Brief Summary
This non-interventional, prospective, non-controlled study of Xamiol® Gel, a fixed combination of calcipotriol and betamethason dipropionate, shall investigate in daily routine the efficacy, tolerability and changes in quality-of-life parameters in patients with scalp psoriasis
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2010
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2010
CompletedFirst Submitted
Initial submission to the registry
January 19, 2010
CompletedFirst Posted
Study publicly available on registry
January 20, 2010
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 1, 2010
CompletedStudy Completion
Last participant's last visit for all outcomes
May 1, 2010
CompletedFebruary 24, 2025
September 1, 2010
4 months
January 19, 2010
February 21, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
Physician's Global Assessment of scalp psoriasis
After approximately 4 weeks
Secondary Outcomes (1)
Patient's Quality of Life
After approximately 4 weeks
Interventions
Once daily application for about 4 weeks
Eligibility Criteria
Patients visiting their attending dermatologist in the primary care clinic
You may qualify if:
- Patients with scalp psoriasis if a treatment with Xamiol® gel is planned anyway
You may not qualify if:
- Contraindications of Xamiol® Gel listed in the German package insert
- Pretreatment with Xamiol® within the last 4 weeks
- Systemic treatment of psoriasis
- UV light therapy
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- LEO Pharmalead
Study Sites (1)
University Clinical Schleswig-Holstein, Campus Kiel
Kiel, 24105, Germany
Study Officials
- PRINCIPAL INVESTIGATOR
Ulrich Mrowietz, MD
University Clinic Schleswig-Holstein
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
January 19, 2010
First Posted
January 20, 2010
Study Start
January 1, 2010
Primary Completion
May 1, 2010
Study Completion
May 1, 2010
Last Updated
February 24, 2025
Record last verified: 2010-09
Data Sharing
- IPD Sharing
- Will not share